secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cryoport, Inc. (CYRX)
CIK:        0001124524
Form:       8-K
Filed at:   2023-02-23T23:59:59+00:00
Accession:  0001104659-23-024795
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cryoport reports Q4 2022 revenue $60.4M, full-year record $237.3M; guides FY2023 revenue $270-290M
--------------------------------------------------------------------------------

- Full-year 2022 revenue $237.3M, up 7% YoY; commercial therapy revenue up 27% to $16.3M.
- Net loss attributable to common stockholders $45.3M ($0.93/share) vs $283.7M ($6.18/share) in 2021.
- Adjusted EBITDA $13.7M for 2022, down from $21.2M in 2021; Q4 adjusted EBITDA $0.7M.
- Cash and short-term investments $523.3M at year-end; repurchased 1.6M shares for $37.9M in 2022.
- FY2023 revenue guidance $270-290M (18% growth at midpoint); supporting 654 clinical trials and 10 commercial therapies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124524/000110465923024795/0001104659-23-024795-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124524/000110465923024795/tm237715d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-024795

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer